Dr. Vaduganathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Brigham and Women's Hospital
75 Francis St.
Boston, MA 02115
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2015 - 2019
Massachusetts General HospitalFellowship, Cardiovascular Disease, 2016 - 2017- Massachusetts General HospitalResidency, Internal Medicine, 2012 - 2015
Northwestern University The Feinberg School of MedicineClass of 2012
Certifications & Licensure
MA State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- 15 citationsSGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.Vennela Avula, Garima Sharma, Mikhail N Kosiborod, Muthiah Vaduganathan, Tomas G Neilan
JACC. Heart Failure. 2024-01-01 - 31 citationsPractical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC.Antoni Bayes-Genis, Kieran F Docherty, Mark C Petrie, James L Januzzi, Christian Mueller
European Journal of Heart Failure. 2023-11-01 - 1 citationsDuration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial.John W Ostrominski, Brian L Claggett, Milton Packer, Marc A Pfeffer, Carolyn S P Lam
Journal of Cardiac Failure. 2023-11-01
Journal Articles
- Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical PracticeMuthiah Vaduganathan, Javed Butler, Paul A Heidenreich, Michelle M Kittleson, Anjali Tiku Owens, Pamela N Peterson, Clyde W Yancy, Gregg C Fonarow, JAMA Cardiology
- Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Cardiovascular DiseaseMichael C Honigberg, Darren K Mcguire, Muthiah Vaduganathan, JAMA Cardiology
- Emerging Trends in Financing of Adult Heart Transplantation in the United StatesMuthiah Vaduganathan, Josef Stehlik, Mandeep R Mehra, JACC: Cardiovascular Imaging
- Join now to see all
Authored Content
- Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Cardiovascular DiseaseJune 2020
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19April 2020
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19April 2020
- Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients with Type 2 DiabetesMarch 2018
- Oral Anticoagulation in Patients with Liver DiseaseMarch 2018
- Join now to see all
Press Mentions
LookAHEAD Cardiac Biomarker Ancillary Study | JACC | AHA 2024November 16th, 2024- Part Two: Time to Significant Benefit of Finerenone in Patients with Heart Failure | JACC | HFSA 2024October 4th, 2024
- Event-Free Survival Extended with Long-Term Finerenone in Heart FailureSeptember 30th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
